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Background: The aim of this study is to review the long-term outcomes of bilateral lung transplantation (BLTx) in
our institution and examine the potential issues that may influence outcomes in a low-volume center.
Methods: A retrospective review of BLTx performed in our institution between July 2006 and December 2012 was
conducted. Standardized donor selection, procurement, and preservation protocols for brain-dead donors were
applied. Measured outcomes were in-hospital mortality and actuarial survival using the Kaplan-Meier method.
Results: Twenty-five consecutive patients (13 male, 12 female) underwent BLTx with a mean age of 41.8 ± 13.5
years. Before LTx, the mean body mass index was 18.3 ± 3.1 kg/m2. Seven of these patients (28%) required oxygen
supplementation at rest before LTx, while the remaining patients (72%) required noninvasive mechanical ventilation
(n = 6, 24%), invasive mechanical ventilation (n = 9, 36%) or extracorporeal membrane oxygenation (ECMO) (n = 3,
12%). The lung grafts were procured from brain-dead donors with the mean age of 26.8 ± 11.4 year and the best
PaO2 / FiO2 ratio of 513 ± 77 before procurement. All cross match results between same-race donors and recipients
were negative. The percentage of same-sex matching and CMV mismatching were 64% and 4%, respectively. The
mean time listed on the transplant list was 308 ± 261 days. The mean ischemic time for the first and second grafts
were 222 ± 62 and 361 ± 67 minutes. During transplantation, 22 (88%) patients depended on ECMO and one (4%)
on cardiopulmonary bypass support. All but two patients (82%) were discharged home in good condition; two (8%)
patients died within 3 months after BLTx. The cumulative survival rates at 1-, 2-, 3-, and 5-years were 88%, 83%,
72%, and 72%, respectively.
Conclusions: Although the comparatively few annual LTx performed is consistent with the low donation rate, our
single-center growing experience demonstrates that good post-lung transplant outcomes can be achieved at a
low-volume LTx center.
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Owing to the development of improved immunosup-
pressants and refinements in surgical technique, lung
transplantation (LTx) has become the standard of care
for most causes of end-stage lung disease over the last
two decades. The first LTx in Taiwan was performed in* Correspondence: ntuhsu@gmail.com
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unless otherwise stated.1991, but by the end of 2013, the total number of LTx
was less than 150 cases due to the shortage of suitable
cadaveric lung donors. Currently, there are eight medical
centers authorized to perform LTx in Taiwan; however,
none of them have been able to reach 10 LTx per year.
The official transplantation report published in 2011 by
the Taiwan Organ Registry and Sharing Center (TORSC)
demonstrated that the national LTx survival rates (or the
average survival rates of all LTx centers) from January
2006 to December 2010 in Taiwan were 65% at one year
and 56% at 3 years, respectively. These numbers arehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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International Society for Heart and Lung Transplant-
ation (ISHLT) [1]. This has led some physicians to re-
examine the risks and benefits of LTx, leading to delayed
referral of potential candidates. In the TORSC report,
however, some important issues affecting the LTx out-
comes were not well-examined. The national donation
rate, the varieties between different transplant centers,
the effects of transplant center volume, the urgency-
based organ allocation policy, and donor and recipient
matching all impact survival after LTx. In an attempt to
address the void of information and provide more clar-
ity regarding the current information, we report our
single-center experience with long-term outcomes after
bilateral LTx (BLTx) and evaluate the effects of several




We performed a retrospective analysis of consecutive
patients who have undergone BLTx at the National
Taiwan University hospital from July 2006 to December
2012, excluding heart-lung transplantation. Donor, recipi-
ent, and surgical data were extracted from patient charts
and the Transplant database. This study was approved by
the Institutional Review Board of National Taiwan Univer-
sity Hospital, with the informed consent waived.
Recipient and donor selection
The criteria for donor and recipient selection were iden-
tical to those established by the ISHLT. All donor lungs
were retrieved from brain-dead donors. In Taiwan, the
preference in donor allocation is given to patients with
the highest short-term risk of death. When the waiting-
lists were listed on the national organ allocation net-
work, they were categorized into three different status
according to the disease severity. The status II meant
the patient has been qualified as a waiting list and could
wait for a suitable donor. The status IB meant the
waiting-list needed to be hospitalized due to disease pro-
gress. The status IA meant the waiting-list has already
relied on ventilator or ECMO support. The first priority
of lung donor allocation was the severity of recipient’s
disease, which meant that the more severe the under-
lying disease, the more preference for organ allocation.
Because the total national number of LTx in Taiwan was
less than 150 cases, the post-LTx survival did not take
into account for organ allocation. The other priorities of
organ allocation included the results of cross-matching
between donor and recipient, and size matching. Be-
cause Taiwan is a small island and the national trans-
plant network run well, we have enough time to perform
the cross-matching tests and wait for the results beforeperforming LTx. Therefore, the cross-matching results
between donors and recipients were all negative in our
LTx patients.
Lung transplant protocols
During the study period 2006 to 2012, standardized pro-
tocols were applied; these have been described previ-
ously but are summarized briefly here [2]. All donors
were evaluated by our institution’s transplant surgeons.
Techniques used to assess lung quality included chest
radiography, arterial blood gas, bronchoscopy, and visual
inspection. For donor lung procurement, a bolus injec-
tion of prostaglandin E1 500μg was administered into
the main pulmonary artery immediately before cross-
clamping the aorta. The donor lung was perfused with
70 mL/kg of Perfadex (Vitrolife AB, Goteborg, Sweden)
anterograde through the main pulmonary artery and 1
liter of Perfadex retrograde through the pulmonary
veins. BLTx was carried out through a clamshell incision
from the 4th or 5th intercostal space. The intraoperative
extracorporeal membrane oxygenation (ECMO) system
was routinely set up to provide adequate hemodynamic
support during BLTx when the recipient already
depended on ventilator or ECMO support before BLTx,
or when the recipient could not tolerate pneumonec-
tomy of the first native lung. In general, ECMO was
weaned off in the operating room after BLTx. However,
if there were signs of severe reperfusion lung edema or
acute primary graft dysfunction that did not allow the
transplanted lung to function well, ECMO was continued
during transport from the operating room to the intensive
care unit (ICU). Protective ventilator management with
low tidal volumes (6 mL/kg of the donor body weight)
and high positive end-expiratory pressure was used post-
operatively. Early adequate enteral nutrition was achieved
via nasal feeding tube inserted to the proximal jejunum
under endoscopic guidance 2 days after LTx. A triple drug
regimen, including a calcineurin inhibitor (cyclosporine or
tacrolimus), an antimetabolite (azathioprine or mycophe-
nolate mofetil), and corticosteroids, was used for mainten-
ance immunosuppression. The choice of antibiotics was
based on the results of sputum culture from donor and re-
cipient. In the early post-transplant period, prophylactic
valganciclovir was routinely used to prevent cytomegalo-
virus. Voriconazole was used for fungus and yeast if infec-
tion was suspected.
Statistical analysis
Continuous data are expressed as the mean with the
standard deviation; proportions are represented as num-
bers (%). Categorical data are presented as a frequency
and percentage. Cumulative survival following lung
transplantation was determined using the Kaplan-Meier
method. Overall survival was determined by the time
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December 31, 2013.Results
Recipient characteristics
The total cohort included 25 consecutive patients (13
men, 12 women), with a mean age of 41.8 ± 13.5 years
(range, 18 ~ 67 years). At the time of LTx, mean recipient
body mass index (BMI) was 18.3 ± 3.1 kg/m2 (range, 12.9 -
24.1 kg/m2); five recipients (20%) were hepatitis B virus
(HBV) carriers. Before LTx, 7 (28%) patients required oxy-
gen supplementation at rest, 6 (24%) patients needed non-
invasive mechanical ventilator (MV) support, 9 (36%)
patients depended on invasive MV support (IMV), and 3
(12%) patients were supported by ECMO combined with
IMV. The underlying diseases necessitating transplant in-
cluded bronchiectasis (n = 7), lymphangioleiomyomatosis
(n = 5), bronchiolitis obliterans (n = 4), pulmonary arterial
hypertension (n = 3), pneumoconiosis (n = 3), idiopathic
pulmonary fibrosis (n = 2), and chronic obstructive pul-
monary disease (COPD) (n = 1) (Table 1).Table 1 Demographic and preoperative characteristics
Recipient demographic No. or % or
mean ± SD rang
Age, year 41.8 ± 13.5 18 ~ 67
BMI, kg/m2 18.3 ± 3.1 12.9 - 24.1
Sex Female 12 48%
HBV carrier 5 20%
Respiratory status before LTx
Under oxygen at rest 7 28%
Noninvasive MV 6 24%
Invasive MV 9 36%
ECMO (+invasive MV) 3 12%
Diagnosis
Bronchiectasis 7 28%
Not associated with CF 6 24%







BMI: Body mass index; HBV: Hepatitis B virus.
MV: Mechanical Ventilator.
ECMO: Extracorporeal membrane oxygenation.
CF: Cystic fibrosis.
LAM: Lymphangioleiomyomatosis; BO: Bronchiolitis obliterans.
PAH: Pulmonary arterial hypertension; IPF: Idiopathic pulmonary fibrosis.
COPD: Chronic obstructive pulmonary disease.Donor characteristics
The mean donor age was 27 ± 11 years (range, 15 ~ 53
years). Seven (28%) donors were female and 8 (32%) do-
nors had a smoking history. The causes of brain death
were head trauma (n = 18, 72%), cerebrovascular acci-
dents (n = 5, 20%), and other conditions (n = 2, 8%). Be-
fore harvest, the best ratio of arterial partial pressure of
oxygen (PaO2) to 100% fraction of inspired oxygen
(FiO2) was 513 ± 77 (range, 350 ~ 674) and the mean
time dependent on the ventilator was 66 ± 52 hours
(range, 23 ~ 252 hours) (Table 2). The transplant vari-
ables used to match donors and recipients are presented
in Table 2 and included negative cross-match results
(100%), same ethnic origin (100%), gender (64%), identi-
cal blood group (68%), compatible blood group (32%),
and cytomegalovirus (CMV) status (96%).
Operative and postoperative characteristics
The mean time between placement on the waiting list
and transplantation was 308 ± 261 days (range 19 ~ 1064
days). The ischemic times for the first and second grafts
were 222 ± 62 minutes (range 125 ~ 337 minutes) and
361 ± 67 minutes (range 253 ~ 463 minutes). ECMO wasTable 2 Donor characteristics
Donor demographic No. or % or
mean ± SD range
Donor variables
Age, years 26.8 ± 11.4 15 ~ 53
Female 7 28%
Cigarette use 8 32%
Cause of brain death
Head trauma 18 72%
CVA 5 20%
Others 2 8%
Best PaO2/FiO2 ratio 513 ± 77 350 - 674
Time on ventilator, hours 66 ± 52 23 - 252
Transplant variables
Cross-match negative 25 100%
Same-race matching 25 100%





D (+), R (+) 24 96%
D (+), R (-) 1 4%
CVA: Cerebrovascular accident.
PaO2/FiO2: Arterial partial pressure of oxygen/a fraction of inspired oxygen.
CMV: Cytomegalovirus; D (+): Positive CMV result of Donor serum.
R (+): Positive CMV result of recipient serum.
R (-): Negative CMV result of recipient serum.
Table 4 Postoperative outcome
Demographics No. or % or
mean ± SD range
Postoperative
ICU length of stay, days 45 ± 24 15 - 98
Hospital length of stay, days 76 ± 45 21 - 206
Cause of death within less than 90 days 2 8%
Primary graft failure 1 4%
Pulmonary infection 1 4%
Cause of death on day 90 or thereafter 4 16%
Pulmonary infection 2 8%
Sepsis 1 4%
BOS 1 4%
Survival, days 1272 ± 784 21 - 2544
ICU: Intensive care unit.
BOS: Bronchiolitis obliterans syndrome.
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1 recipient (4%) required the heart-lung machine for car-
diopulmonary bypass. For maximal utilization of available
resources, 13 (52%) donor lungs underwent concomitant
resection of unhealthy areas intraoperatively. Seven of 13
donor surgeries were anatomical lobectomies (three for
downsizing resection and four for localized pathological
present), and the others were volume-reduction surgeries
for size mismatching (Table 3).
Survival
The intensive care stay after BLTx was 45 ± 24 days
(range 15 ~ 98 days), and the total hospital stay was 76 ±
45 days (range 21 ~ 206 days). Two recipients died (1
primary graft failure, 1 pulmonary infection) within 3
months; the other recipients (92%) were discharged
home without incident and followed up regularly as out-
patients. By the end of the study period, four of these
discharged recipients had died. The causes of death were
pulmonary infection (n = 2), sepsis (n = 1), and bron-
chiolitis obliterans syndrome (n = 1) (Table 4). The
mean survival of all 25 patients was 1272 ± 784 days
(range 21 ~ 2544 days). Kaplan-Meier survival for all
patients after BLTx at 1-, 2-, 3-, 5- years was 88%, 83%,
72%, and 72%, respectively (Figure 1).
Discussion
This retrospective study presents the long-term outcome
of 25 consecutive patients receiving BLTx in a low-volume
center. This report demonstrated that the satisfactory out-
come can be achieved using the urgency-based organ allo-
cation criteria in a donor-scare country.
According to the TORSC report, the average annual
organ donation rate after brain death in Taiwan wasTable 3 Operative data
Demographics No. or % or
mean ± SD range
Time on waiting list, days 308 ± 261 19 - 1064
Intraoperative
Ischemic time, minutes
First graft 222 ± 62 125 - 337
Second graft 361 ± 67 253 - 463







Other graft size reductions 6 24%
ECMO: Extracorporeal membrane oxygenation.
CPB: Cardiopulmonary bypass.around 6.5 per million of population (PMP) in recent
years, which is far below that of Spain (35.3 PMP),
Belgium (30.1 PMP), Portugal (28.1 PMP), the U.S.A.
(25.6 PMP) and France (25 PMP). The low donation rate
in Taiwan creates a severe shortage of donor lungs and
limits the annual number of LTx. Ample evidence now
exists confirming a relationship between surgical out-
come and volume of the procedure, which becomes es-
pecially important for complex procedures such as
transplantation [3-6]. Weiss et al. reported that the cu-
mulative risk of mortality at 30 days, 1 year, and 5 years
after LTx was highly dependent on volume. In general,
high-volume centers (those centers achieving an average
of 20 LTx per year) had superior short- and long-term
outcomes, and low-volume centers (those centers achiev-
ing less than 10 LTx per year) have alarmingly high mor-
tality rates. In Taiwan, none of the seven authorized LTx
centers have been able to reach 10 LTx per year due to the
low organ donation rate. Based on these findings, it isFigure 1 Kaplan-Meier actuarial survival after bilateral
lung transplantation.
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LTx outcomes in Taiwan is worse than those reported by
the ISHLT. Interestingly, some low-volume centers have
been able to produce excellent outcomes, implying that
factors influencing mortality after LTx are far more com-
plex than simply volume. Weiss et al. speculate that low-
volume centers may be able to provide similar outcomes
as the high-volume centers if they are equipped with spe-
cialized staff, integrated patient support systems, and a
culture of excellence. These characteristics provide a
benchmark for LTx centers to strive for, no matter the size
or volume of the center.
The other important issue that significantly impacts
transplant outcomes is the organ allocation system. The
new allocation rules implemented in France since 2007,
which prioritize allocation of donor lungs to candidates
with conditions posing an immediate threat to life, are
similar to those in Taiwan. The national LTx report from
France demonstrated that the survival results for emer-
gency LTx (ELTx) were worse than those for non-urgent
LTx [7]. Survival rates in the ELTx group were 64.5%
and 55% at 1 and 2 years, respectively, which were sig-
nificantly lower than the regular, nonurgent LTx group
(77% and 71%, respectively). As with France’s experience,
Spain and the United States also have similarly poor out-
comes for emergent or urgent LTx [8,9]. According to
the United Network for Organ Sharing (UNOS) data,
patients on MV or ECMO before LTx had decreased
survival after LTx [10]. The 1-year survival associated
with ventilator and ECMO support groups were 67.7%
and 57.6%, respectively, which were both inferior to
those in the high lung allocation score group. Based on
these findings, it is reasonable to conclude that this kind
of urgency-based allocation policy may contribute to fu-
tile and unsuccessful transplantation, especially for low-
volume, limited experience LTx centers in donor-scare
countries, such as those in Taiwan.
Our report is consistent with the conclusion that lung
allocation policy has great influence on the distribution
of underlying disease indications for LTx. Although
COPD was one of the major diagnoses for LTx in the
UNOS and ISHLT reports, only one patient with COPD
(4%) received LTx in our study population [1,11]. This
unique phenomenon may result from the urgency-based
lung allocation system in Taiwan. These allocation rules
could potentially make access to LTx more difficult for
patients not fulfilling the emergency criteria when donor
lungs are scarce, gradually leading to an increase in
waiting-list mortality for non-urgent patients, such as
those with COPD.
In this study, eighteen (72%) patients were already
dependent on MV or ECMO support prior to LTx. In
order to provide adequate hemodynamic support during
LTx, ECMO was used preferentially as an alternative tocardiopulmonary bypass (CPB). We prefer the ECMO
circuit to assist LTx instead of CPB for several reasons.
First, modern ECMO technology, including replacement
of silicone oxygenators, the introduction of heparin-
bonded circuits, and new centrifugal pumps, gives ECMO
the capacity to support gas exchange without the need for
high-dose heparin administration or anticoagulation ther-
apy. Second, our institution is one of the highest-volume
ECMO centers in the world. In our institution since 1994,
more than 1,950 patients have been treated with ECMO
for sundry causes of cardiopulmonary collapse. Therefore,
the refined technical aspects of ECMO combined with the
experience using ECMO in our hospital significantly de-
creases the incidence of major ECMO-attributed compli-
cations, including bleeding and peripheral access-related
limb ischemia, in our transplant population. Finally,
ECMO can provide a bridge to transplantation in pa-
tients unresponsive to maximal pulmonary-respiratory
support [12-15]. In this report, of 23 patients (92%) re-
ceiving BLTx under ECMO support, only one needed to
switch to traditional cardiopulmonary bypass (due to
severe hemodynamic instability). Furthermore, ECMO
allowed 3 (12%) patients cardiopulmonary failure to be
stabilized before LTx and thus be successfully bridged
(up to 86 days) to BLTx in a high-urgency setting; each
of these patients was weaned off ECMO smoothly and
discharged without any complications.
The 1-, 3-, and 5-year survival rates after BLTx in this
study are similar to those of the Japanese registry report
(86%, 79%, and 73%), and are slightly superior to those
from UNOS (84%, 66%, 51%) and ISHLT (79%, 64%,
53%) [11,16,17]. Given the small sample size in our
study, we can only speculate on the reasons for our
improved outcomes. Most likely, a combination of special-
ized staff, operative technique, and optimal recipient-
donor matching (100% cross match and race matching,
and only 4% CMV mismatching) is responsible for these
outcomes; however, further investigation of these trends is
warranted to confirm this speculation.
This study is limited by its single-institution, small sam-
ple size, and retrospective nature. Moreover, there was no
control group to reduce the influence of selection bias.
However, a control group may present ethical challenges
because LTx is a promising, feasible and lifesaving proced-
ure for patients with end-stage pulmonary disease.Conclusions
Owing to refined surgical technique, adequate periopera-
tive support, and improved postoperative care, we believe
LTx can be performed with acceptable post-transplant
mortality and satisfactory long-term outcomes in a low-
volume center such as ours using the urgency-based organ
allocation criteria.
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